| Literature DB >> 32984632 |
Abdelouahab Laamari1, Naouelle Azzag1, Safia Tennah1, Salima-Yamina Derdour1, Bernard China2, Ryhan Bouabdallah1, Farida Ghalmi1.
Abstract
INTRODUCTION: Horses (Equus caballus) are susceptible to tick-borne diseases. Two of them, Lyme borreliosis due to Borrelia burgdorferi and granulocytic anaplasmosis due to Anaplasma phagocytophilum were investigated in Algerian horses. The diseases have been less extensively studied in horses and results pertinent to Algeria have not been published.Entities:
Keywords: Anaplasma phagocytophilum; Borrelia burgdorferi; co-infection; horses; seroprevalence
Year: 2020 PMID: 32984632 PMCID: PMC7497754 DOI: 10.2478/jvetres-2020-0045
Source DB: PubMed Journal: J Vet Res ISSN: 2450-7393 Impact factor: 1.744
Characteristics of the study group considering gender, age, and breed of sampled horses
| Variable | Healthy group (n = 108) | Affected group (n = 20) |
|---|---|---|
| Gender | ||
| Male | 62 | 14 |
| Female | 46 | 6 |
| Age (years) | ||
| 1–11 | 54 | 14 |
| 12–16 | 33 | 3 |
| 17–25 | 21 | 3 |
| Breed | ||
| Arabian | 85 | 15 |
| Barb | 13 | 2 |
| Arab–Barb | 10 | 3 |
Seroprevalence of Borrelia burgdorferi and Anaplasma phagocytophilum by ELISA and IFAT
| Pathogen | IFAT (n = 128) | ELISA (n = 128) | ||
|---|---|---|---|---|
| Positive | Seroprevalence (%) (95% CI) | Positive | Seroprevalence (%) (95% CI) | |
| 18 | 14.1 (9.1–21.1) | 6 | 4.7 (2.2–9.9) | |
| 15 | 11.7 (7.2–18.4) | 20 | 15.6 (10.4–22.9) | |
| 10 | 7.8 (4.3–13.8) | 13 | 10.2 (6.0–16.7) | |
| 28 | 21.87 (13.79–28.20) | 19 | 14.84 (7.86–20.13) | |
| 25 | 19.53 (12.06–25.93) | 33 | 25.87 (17.34–32.65) |
The prevalence was significantly different by IFAT and ELISA (P < 0.05)
The prevalence was not significantly different by IFAT and ELISA (P > 0.05)
The prevalence was not significantly different between methods (P > 0.05)
Seroprevalence of Borrelia burgdorferi and Anaplasma phagocytophilum regarding breed, sex, age, and health status
| Variable | IFAT + (%; 95% CI) | ELISA + (%; 95% CI) | IFAT + (%; 95% CI) | ELISA + (%; 95% CI) |
|---|---|---|---|---|
| Age (years) | ||||
| 1–11 (n = 54) | 22 (40.7; 28.7–54.0) | 26 (48.1; 35.4–61.2) | 22 (40.7; 28.7–54.0) | 10 (18.5; 10.4–30.9) |
| 12–16 (n = 33) | 3 (9.1; 3.1–23.6) | 4 (12.1; 4.8–27.3) | 3 (9.1; 3.1–23.6) | 6 (18.2; 8.6–34.4) |
| 17–25 (n = 21) | 0 (0) | 3 (14.3; 5.0–34.6) | 3 (14.3; 5.0–34.6) | 3 (14.3; 5.0–34.6) |
| P value | <0.01 SS | <0.01 SS | <0.01 SS | 0.9 NS |
| Gender | ||||
| Male (n = 62) | 12 (19.4; 11.4–30.8) | 9 (14.5; 7.8–25.4) | 15 (24.2; 15.2–36.2) | 14 (22.6; 13.9–34.4) |
| Female (n = 46) | 13 (28.3; 17.3–42.6) | 24 (52.2; 38.1–65.9) | 13 (28.3; 17.3–42.6) | 5 (10.9; 4.7–23.0) |
| P value | 0.3 NS | <0.01 SS | 0.6 NS | 0.1 NS |
| Breed | ||||
| Arabian (n = 85) | 20 (23.5; 15.8–33.6) | 22 (25.9; 17.8–36.1) | 20 (23.5; 15.8–33.6) | 14 (16.5; 10.1–25.8) |
| Barb (n = 13) | 1(7.7; 1.4–33.3) | 5 (38.5; 17.7–64.5) | 1 (7.7; 1.4–33.3) | 1 (7.7; 1.4–33.3) |
| Arab–Barb (n = 10) P value | 4 (40; 16.8–68.7) 0.2 NS | 6 (60; 31.2–83.2) 0.07 NS | 7 (70; 39.7–89.2) <0.01 SS | 4 (40; 16.8–68.7) 0.1 NS |
| P value | 0.2 NS | 0.07 NS | <0.01 SS | 0.1 NS |
| Clinical signs | ||||
| Yes (n = 20) | 9 (45; 25.8–65.8) | 10 (50; 29.9–70.1) | 11 (55; 34.2–74.2) | 7 (35; 18.1–56.7) |
| No (n = 108) | 16 (14.8; 9.3–22.7) | 23 (21.3; 14.6–29.9) | 17 (15.7; 10.1–23.8) | 12 (11.1; 6.5–18.4) |
| P value | <0.01 SS | <0.05 S | <0.01 SS | <0.05 S |
Agreement analysis between IFAT and ELISA tests
| IFAT | Statistics | ||||
|---|---|---|---|---|---|
| ELISA | Sera | Positive | Negative | Total | κ = 0.56 McNemar P < 0.01 SS |
| Positive | 15 | 4 | 19 | % agreement = 86.7 | |
| Negative | 13 | 96 | 109 | Relative sensitivity = 53.6% | |
| Total | 28 | 100 | 128 | Relative specificity = 96% | |
| IFAT | Statistics | ||||
| ELISA | Sera | Positive | Negative | Total | κ = 0.61 McNemar P < 0.01 SS |
| Positive | 20 | 13 | 33 | % agreement = 85.9 | |
| Negative | 5 | 90 | 95 | Relative sensitivity = 80% | |
| Total | 25 | 103 | 128 | Relative specificity = 87.4% | |
Seroprevalence of A. phagocytophilum around the world
| Country | Year | Technique | n | Positive | Prevalence (%) | Lower limit | Upper limit | Reference |
|---|---|---|---|---|---|---|---|---|
| Algeria | 2018 | IFAT | 128 | 25 | 19.53 | 12.66 | 26.40 | this study |
| Bulgaria | 2018 | ELISA | 155 | 31 | 20.00 | 13.70 | 26.30 | |
| Canada | 2015 | SNAP 4Dx | 376 | 2 | 5.31 | 0 | 1.27 | |
| Czech Republic | 2011 | IFAT | 92 | 67 | 72.8 | 63.74 | 81.91 | |
| Denmark | 2010 | SNAP 4Dx | 390 | 87 | 22.31 | 18.18 | 26.44 | |
| France | 2005 | ELISA | 424 | 48 | 11.32 | 8.30 | 14.33 | |
| France | 2009 | ELISA | 408 | 55 | 13.48 | 10,17 | 16.79 | |
| Guatemala | 2005 | IFAT | 74 | 10 | 13.51 | 5.72 | 21.30 | |
| Italy | 2003 | IFAT | 561 | 2 | 3.56 | 0 | 8.50 | |
| Italy | 2008 | IFAT | 793 | 134 | 16.90 | 14.29 | 19.51 | |
| Italy | 2008 | IFAT | 154 | 12 | 7.79 | 3.56 | 12.03 | |
| Italy | 2010 | IFAT | 135 | 23 | 17.04 | 10.69 | 23.38 | |
| Italy | 2019 | IFAT | 479 | 109 | 22.76 | 19.00 | 26.51 | |
| Mongolia | 2018 | IFAT | 216 | 91 | 42.13 | 35.54 | 48.71 | |
| Tunisia | 2014 | IFAT | 343 | 56 | 16.33 | 12.41 | 20.24 |
Seroprevalence of B. burgforferi in the world
| Country | Year | Method | n | Positive | Prevalence (%) | Lower limit | Upper limit | Reference |
|---|---|---|---|---|---|---|---|---|
| Algeria | 2019 | IFAT | 128 | 28 | 21.88 | 14.71 | 29.04 | this study |
| Brazil | 2018 | ELISA | 367 | 214 | 58.31 | 53.27 | 63.36 | |
| Canada | 2015 | SNAP 4Dx | 376 | 6 | 1.60 | 0.033 | 2.86 | |
| France | 2010 | SNAP 4Dx | 408 | 134 | 32.84 | 28.29 | 37.40 | |
| French | 2010 | SNAP 4Dx | 49 | 0 | 0 | 0 | 0 | |
| Italy | 2013 | IFAT | 300 | 21 | 7.00 | 4.11 | 9.89 | |
| Italy | 2012 | SNAP 4Dx | 98 | 15 | 15.31 | 8.18 | 22.43 | |
| Italy | 2012 | IFAT | 386 | 94 | 24.35 | 20.07 | 28.63 | |
| Korea | 2016 | ELISA | 727 | 40 | 5.50 | 3.84 | 7.16 | |
| Mexico | 2001 | IFAT | 100 | 34 | 34.00 | 24.72 | 43.28 | |
| Poland | 2008 | ELISA | 395 | 101 | 25.57 | 21.27 | 29.87 | |
| Romania | 2011 | ELISA | 260 | 31 | 11.92 | 7.98 | 15.86 | |
| Sub-Saharan | 2010 | SNAP 4Dx | 113 | 0 | 0 | 0 | 0 | |
| Turkey | 2008 | ELISA | 300 | 18 | 6.00 | 3.31 | 8.69 | |
| USA | 2012 | ELISA WB and | 2100 | 175 | 8.33 | 7.15 | 9.52 |